BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Trial Profile

BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs BAX 930 (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions; First in man
  • Sponsors Baxalta; Baxter Healthcare Corporation
  • Most Recent Events

    • 14 Sep 2017 Results published in the Blood
    • 10 Jun 2017 Biomarkers information updated
    • 22 Mar 2017 According to a Shire media release, based on data from this study United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients with a constitutional deficiency of ADAMTS13.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top